| Description |
1 online resource |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
|
text file PDF rda |
| Bibliography |
Includes bibliographical references. |
| Contents |
Preface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times. |
| Summary |
"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. But their sticker shock-the drug was dubbed "the $1,000-a-day pill"-intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. His account travels between public and private labs, Wall Street and corporate boardrooms, public health meetings and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures"-- Provided by publisher. |
| Note |
Description based on print version record and CIP data provided by publisher. |
| Language |
In English. |
| Access |
Open Access EbpS |
| Subject |
Gilead Sciences (Firm)
|
|
Gilead Sciences (Firm)
|
|
Drugs -- Prices -- United States.
|
|
Pharmaceutical industry -- Economic aspects -- United States.
|
|
Drug development -- Economic aspects -- United States.
|
|
Sofosbuvir -- Prices -- United States.
|
|
Hepatitis C -- Treatment -- Prices -- United States.
|
|
Médicaments -- Prix -- États-Unis.
|
|
Industrie pharmaceutique -- Aspect économique -- États-Unis.
|
|
Médicaments -- Développement -- Aspect économique -- États-Unis.
|
|
Hépatite C -- Traitement -- Prix -- États-Unis.
|
|
Drugs -- Prices
|
|
Pharmaceutical industry -- Economic aspects
|
|
United States
|
|
MEDICAL / Ethics.
|
| Other Form: |
Print version: Roy, Victor, 1986- Capitalizing a cure Oakland, California : University of California Press, [2023] 9780520388710 (DLC) 2022023732 |
| ISBN |
0520388720 |
|
9780520388727 (electronic bk.) |
|
9780520388710 (paperback) |
| Standard No. |
10.1525/9780520388727 doi |
|
AU@ 000072774619 |
|
